Ratings Cresco Labs Inc. OTC Markets

Equities

CRLB.F

CA22587M1068

Market Closed - OTC Markets 03:59:59 2024-03-28 pm EDT 5-day change 1st Jan Change
2.07 USD -7.17% Intraday chart for Cresco Labs Inc. -5.91% +52.68%

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • Low profitability weakens the company.
  • The company is in debt and has limited leeway for investment
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
+52.68% 780M -
+33.46% 701B
C+
+26.24% 571B
B
+0.93% 381B
C+
+21.03% 334B
B-
+17.51% 319B
C+
+0.74% 210B
B+
+2.95% 210B
B-
-6.05% 201B
A+
-3.61% 157B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes